Science Behind Insulin Delivery

Similar documents
Clinical Evidence for Insulin Pump Therapy

Pumps & Sensors made easy. OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University

Insulin pump therapy. Healthy Living with Diabetes

MINIMED 670G HYBRID CLOSED LOOP (HCL) IN THE FIELD

Diabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE

Using the Bolus Wizard Calculator

Pumping Insulin is it for your patients?

CareLink. software REPORT REFERENCE GUIDE. Management Software for Diabetes

Report Reference Guide

INSPIRED BY GIVE HIM MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs.

INSPIRED BY GIVE HER MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs.

The Realities of Technology in Type 1 Diabetes

Technology for Diabetes: 101 Basic Rules of the Road. Karen Hamon RN, BSN, CDE Stephen Stone MD, FAAP Neil H. White, MD, CDE

Welcome to CareLink Pro

Getting Started. Learning Guide. with Insulin Pump Therapy. PUMP Foundations. for the MiniMed 530G with Enlite

Clinical Value and Evidence of Continuous Glucose Monitoring

Performance-powered. The OneTouch. Ping insulin pump and meter-remote.

CGM Therapy Expert Program

This certificate-level program is non-sponsored.

Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical

The Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes

THERAPY MANAGEMENT SOFTWARE FOR DIABETES

Self-Monitoring Blood Glucose (SMBG) Frequency & Pattern Tool

Insulin Pump Therapy

Designed with your patients lives in mind

Insulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK)

Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)

Diabetes Management in Toddlers/Preschoolers (<6 yo)

THERAPY MANAGEMENT SOFTWARE FOR DIABETES

THE MINIMED 670G SYSTEM SCHOOL NURSE GUIDE

WHAT CAN I DO TO REDUCE MY RISK OF DEVELOPING THE COMPLICATIONS OF TYPE 1 DIABETES?

Insulin Pump Therapy. WakeMed Children s Endocrinology & Diabetes WakeMed Health & Hospitals Version 1.3, rev 5/21/13 MP

New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011

Type I Type II Insulin Resistance

Anneli, Martina s daughter In better control with her pump since 2011 MY CHILD HAS TYPE 1 DIABETES

UNDERSTANDING THE BASIC FEATURES AND MANAGEMENT IN THE SCHOOL SETTING CHRISTINE HERTLER RN BSN CDE & MARY MCCARTHY RN CDE

OneTouch Reveal web app Report Reference Guide

Effective Health Care Program

MANAGEMENT OF TYPE 1 DIABETES MELLITUS

CANDY Camp Application

Role of Academia In Achieving Targets in Diabetes Care

INSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد

Insulin Pump Therapy for Type 2

Adjusting Insulin Doses

Real-Time Continuous Glucose Monitoring: From Application to Evaluation

Insulin Pumps and Continuous Glucose Sensors- Embracing Technology. Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education

Report Reference Guide. THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1

Understanding the Assessment and Progress Report

Type 1 DM. CME Away India & Sri Lanka March 23 - April 7, 2018

Hypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier??

Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim

Making the Most of Continuous Glucose Monitoring

What is the role of insulin pumps in the modern day care of patients with Type 1 diabetes?

Confusion Regarding Duration of Insulin Action: A Potential Source for Major Insulin Dose Errors by Bolus Calculators

Position Statement of ADA / EASD 2012

Advances in Diabetes Care Technologies

Advances in Diabetes Care Technologies

USING THE MINIMED 670G SYSTEM. Instructions for the Experienced MiniMed 630G System User

USING THE MINIMED 670G SYSTEM

DIAGNOSIS OF DIABETES NOW WHAT?

MINIMED 640G WITH SMARTGUARD GIVES YOU CONFIDENCE TO TAKE CONTROL OF YOUR DIABETES

EAST OF ENGLAND CHILDREN AND YOUNG PEOPLE S DIABETES NETWORK. Optimising Glycaemic Control for Children and Young People with Diabetes

USE OF INSULIN PUMP FOR THE 1 ST TIME IN A GOVERNMENT HOSPITAL JJ HOSPITAL, MUMBAI

Fine-tuning of The Dose of Insulin Pump

Development of Optimal Kids Insulin Dosing System Formulas for Young Children with Type 1 Diabetes Mellitus

REPORT INTERPRETATION

Case Study: Competitive exercise

Blood Glucose Monitoring System. Copyright 2017 Ascensia Diabetes Care Holdings AG. All rights reserved. diabetes.ascensia.com

Type 1 Diabetes Update Robin Goland, MD

Timely!Insulinization In!Type!2! Diabetes,!When!and!How

Continuous Glucose Monitoring (CGM)

Insulin Prior Authorization with optional Quantity Limit Program Summary

WOULD YOU LIKE MORE CONFIDENCE IN YOUR HYPOGLYCAEMIC CONTROL? SMARTGUARD. PROVIDES PREDICTIVE PROTECTION

Providing Stability to an Unstable Disease

1. Continuous Glucose Monitoring

Mixed Insulins Pick Me

CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Blood glucose Meter Roche USA V6/ PMS 287 Proof Print Number 209 Advanced Owner s Booklet

Akio Ohta, Kaori Arai, Ami Nishine, Yoshiyuki Sada, Hiroyuki Kato, Hisashi Fukuda, Shiko Asai, Yoshio Nagai, Takuyuki Katabami and Yasushi Tanaka

Diabetes Care Publish Ahead of Print, published online June 1, 2009

10:20 AM March 5, B 100% 235 u. 124 mg/dl 3 HRS INSULIN ON BOARD:

Pump Failure Guidelines

SCHOOL HEALTH PLAN: DIABETES

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols. Askiel Bruno, MD, MS Protocol PI

V-Go : Simple to start, easy to use

Background: Brief review of epidemiology, diagnosis, classification and pathophysiology of diabetes mellistus.

How I use the latest technology to investigate and treat a person with Type 1 Diabetes. Dr Pratik Choudhary

TYPE 1 DIABETES AND EXERCISE. Mark W Savage

Basal Bolus Insulin Therapy Frequently Asked Questions

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)

Optimizing Therapy and Clinical Outcomes Using Real-Time Continuous Glucose Monitoring (AADE PRODUCT THEATRE) August 7, 2014 Orlando, FL

Insulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness

DISCOVER THE POWER OF CONNECTION MINIMED 640G

The York Diabetes Care Model

Objectives. The Problem. We ve come a LONG way, Innovations in Diabetes Care and Management. Barbara Walz, RN, BSN, CDE April 26, 2018

These results are supplied for informational purposes only.

Updates in Diabetes Technology

Do fat and protein affect post prandial glycemia in the outpatient real world setting? Neha Verma, MD Robert Melfi, MD

Insulin Pumps Available in Canada

Transcription:

Science Behind Insulin Delivery 1

Overview Objective The objective of this presentation is to demonstrate why insulin pump therapy is more effective than multiple daily shots in delivering superior outcomes Key Points By reviewing this presentation you can learn how an insulin pump: Works more like a healthy pancreas Allows to create multiple basal rates Leads to more accurate bolus dosing Creates more predictable glucose lowering effect 2

Normal Insulin Production: The Pancreas A healthy pancreas releases insulin automatically, on average, every 10-to 14-minutes 1, in amounts appropriate for your varying blood glucose levels. Insulin Normal Insulin Secretion 0 hr 12 hrs 24 hrs Adapted from 1. Marchetti, P, et al. Diabetes, Vol 43, p. 827-839, June 1994. Schematic representation only 3

There Are Big Gaps Between Pancreas Insulin Production and Conventional Therapy NPH and Short-Acting Insulin Injection Injection Normal Insulin Secretion Short-acting Insulin NPH Insulin 0 hr Schematic representation only 12 hrs 24 hrs 4

Intensive Diabetes Management with Injections Is Better But Leaves Room for Opportunity Lantus basal insulin plus rapid-acting insulin before meals Requires 4 5 injections / day Injection Injection Injection Injection Insulin Normal Insulin Secretion Rapid-acting Insulin Lantus 0 hr 12 hrs 24 hrs Schematic representation only. Lantus is a registered trademark of Aventis Pharmaceuticals. 5

When compared to multiple daily injections (MDI), CSII results in: Better metabolic control (improved A1C and fewer excursions) Less hypoglycemia Better patients satisfaction and quality of life CSII is the most physiological method of insulin delivery currently available Consensus statement on use of insulin pumps in pediatrics endorsed by the ADA and European Association for the Study of Diabetes (EASD) Phillip M, Battelino T, Rodriguez H, et al. Diabetes Care. 2007;30:1653-1662. 6

Basal Insulin Needs Vary Throughout the Day 1 0.9 age 3-10 age- 11-20 age 21-60 age >60 units/hour 0.8 0.7 0.6 0.5 0.4 0.3 n=322 12-1a 2-3a 4-5a 6-7a 8-9a 10-11a 12-1p hour 2-3p 4-5p 6-7p 8-9p 10-11p Results indicate it is not reasonable to expect basal insulin needs to be met by a flat rate of insulin delivery for 24 hours. Scheiner, Gary; Boyer, Bret A. Characteristics of basal insulin requirements by age and gender in Type-1 diabetes patients using insulin pump therapy. Diab Res and Clin Prac, 69 (2005) pg. 14-21. 7

Insulin Pump Users Program Multiple Basal Rates According to Their Daily Routine A typical profile of basal insulin rates in CSII. Many people are more active in the late afternoon, and more sedentary after dinner, necessitating adjustment to the basal rate. Note higher basal rate in pre-dawn hours Lenhard MJ, Reeves GD. Arch Intern Med. 2001;161:2293-2300. Reused with permission. 8

Insulin Pumps Also Deliver Customized Boluses for Different Types of Meals Insulin pumps offer smart calculators to help determine how much bolus insulin is needed, and can deliver precise amounts of insulin based on the amount of carbs to be taken. Lenhard MJ, Reeves GD. Arch Intern Med. 2001;161:2293-2300. Reused with permission. 9

Insulin Pumps Use Only Rapid Acting Insulin which Has the Least Intrapatient Variability Pharmacodynamic Variability in Insulin Action* Rapid-acting insulin 16% Rapid-acting insulin has the lowest intrapatient variability Glargine 36% NPH insulin 46% *Percentages represent the coefficients of variation (CV) for insulin action as measured by the maximum glucose infusion rate in these euglycemic glucose clamp studies Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Diabetes Care. 1998;21:1910 1914; Heise T, Nosek L, Rønn BB, et al. Diabetes. 2004; 53:1614-1620. 10

Injections with Long-acting Insulin Can Have Different Glucose Lowering Effects from Day-to-Day Deposit up to a full day s dose of insulin under the skin Expectation is that it will be used at the same rate, day-in and day-out Glucose lowering effect of intermediate and long-acting insulin can vary up to 46% *, which explains drastic day-to-day variations in glucose levels despite using the same amount *Heise T. Diabetes Care. 1998;21:1910 1914; Heise T, Nosek L, Rønn BB, et al. Diabetes. 2004; 53:1614-1620. 11

Medtronic Diabetes 18000 Devonshire Street Northridge, CA 91325 www.minimed.com 1-800-MINIMED (1-800-646-4633) 12